Categories based on incidence: Very often >1/10, often (>1/100, <1/10), unusual (>1/1000, <1/100), rare (>1/10000, <1/1000), very rare (<1/10000), including isolated reports. Gastrointestinal disorders:
Usual: Nausea, diarrhea and abdominal pain.
Very often: Rhinitis (including dry nose, nasal edema, nasal congestion, sneezing, allergic rhinitis), non-specialized symptoms by the nose (e.g. irritation of the nasal route, papular exanthema, erythema, excoriation).
Usual: Ulcer rhinitis, nasosinusitis, epistaxis and pharyngitis.
These symptoms are generally mild (approximately 80% of the cases reported) and require treatment discontinuation in less than 5% of the cases.
Disorders of the nervous system:
Usual: Dizziness, headache and dysgeusia.
Disorders of the sensory organs:
Unusual: Vision disorder.
Disorders of the skin and of the subcutaneous tissue:
Unusual: Edema (facial edema, peripheral edema and edema of the flesh).
Disorders of the immune system:
Unusual: Hypersensitivity reactions such as generalized skin reactions, flush, edema (facial edema, peripheral edema and edema of the flesh), hypertension, arthralgia and itching.
Very rare: Allergic and anaphylactic type reactions such as tachycardia, hypotension, circulatory shock and anaphylactic shock.
Rare: Development of antibodies that inactivate calcitonin. The development of these antibodies does not usually relate to the loss of clinical effectiveness, although their presence in a small percentage of patients after long lasting treatment at high doses of calcitonin may result in reduced response to the product. The presence of antibodies seems not to relate to allergic reactions, which are rare. Downregulation of calcitonin receptors may result in reduced clinical response in a small percentage of patients after long lasting treatment at high doses.
Unusual: Disease similar to flu.